GENE ONLINE|News &
Opinion
Blog

2026-06-02|

Kemper Corporation Issues 15,000 Restricted Stock Units to Two New Executives

by GOAI
Share To

Kemper Corporation granted equity awards to two newly hired executives on June 2, 2026, as a material inducement for their employment. The company issued these awards under its 2026 Inducement Equity Incentive Plan, which provides for the grant of equity-based compensation to individuals who were not previously employees or directors of the firm.

The compensation package includes restricted stock units (RSUs) covering a total of 15,000 shares of Kemper common stock. These units vest in three equal annual installments, contingent upon the executives’ continued employment with the company. The board of directors’ compensation committee approved these grants in accordance with New York Stock Exchange rules, which permit the issuance of equity awards as an inducement for new hires. The company filed the details of these awards with the Securities and Exchange Commission to satisfy regulatory disclosure requirements regarding executive compensation.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 2, 2026

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
LATEST
Braskem Adds Blooming Future Vessel to Maritime Logistics Fleet
2026-06-18
Health Officials Investigate Infant Botulism Outbreak Linked to ByHeart and Nara Formula Products
2026-06-18
Insilico Medicine’s ISM8969 Enters Phase 1 Trial, Advancing Brain-Penetrant NLRP3 Inhibitor for Neuroinflammation and CNS Disorders
2026-06-18
PNC Multifamily Capital Launches $251.4 Million Affordable Housing Investment Fund
2026-06-18
ArcelorMittal, thyssenkrupp, and voestalpine Call for EU Emissions Trading System Reforms to Protect Steel Competitiveness
2026-06-18
Hillman Group and Hillwood Begin Construction on Dallas-Fort Worth Multipurpose Facility
2026-06-18
Six Taipei Biotechs Head to BIO 2026 in San Diego, With Precision Medicine, Drug Delivery, and Bioprocess Innovation in Focus
2026-06-18
Scroll to Top